🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Ischemic vs Bleeding Risks: Do Antiplatelet Guidelines Need Rethinking? These documents have become too technical, too inconsistent, and rely too much on expert opinion, Marco Valgimigli argues. tctmd.com/news/ischemic-… via Yael L. Maxwell

🔍🩸 Looking for a precise way to predict bleeding after PCI and identify HBR patients? 🔢📊 The new PRECISE-HBR score Web Calculator is now available for clinical practice! 🏥💻 Try it out today to enhance patient care and outcomes. Online 👉 precise-hbr.eoc.ch Marco Valgimigli

Congratulations to Dr. Roxana Mehran (Dr Roxana Mehran) on officially assuming the role of Vice President of the American College of Cardiology. This esteemed honor is a reflection of Dr. Mehran’s outstanding contributions to the field of cardiology. We are incredibly proud of her

Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy - joint effort by European Society of Cardiology ACVC, EAPCI, EHRA, WG CVPT and EAHAD Kudos to Dan Atar for leading this complex but important project! academic.oup.com/ehjcvp/article…

After ACS on high-intensity statins, LDL-C, hs-CRP & Lp(a) independently predict future CV events. For Lp(a) & hs-CRP, risk starts at low levels. @VeraBittner2 @DLBhattMD Harvey White Robert Harrington Ph.Gabriel Steg ahajournals.org/doi/full/10.11…

Among HBR pts undergoing #PCI, 1- & 3-month #DAPT was assoc w/ similar risk for ischemic events irrespective of sex. 1-month DAPT 📉 major 🩸compared to 3-month DAPT, risk difference not sig after propensity score stratification jacc.org/doi/10.1016/j.… #JACCINT Professor Vijay Kunadian

Why do #diabetic patients—despite higher thrombotic risk—benefit less from #aspirin+ticagrelor than #ticagrelor monotherapy in #ACS? Find more in our The Lancet correspondence with Prof. Tsigkas. Marco Valgimigli thelancet.com/journals/lance…

#DoTheDropZone in Paris! 📢 20 May, 12:00, #EuroPCR Rm 24: #enVast thrombectomy talk, Prof Marco Valgimigli 📍enVast Tech Suite Lab 3, Hyatt Regency Paris Etoile ➡️20 May, 18:30-20:00: Insight Lounge: An Evening with the Experts ➡️19-22 May, 9:30-15:00: Training Workshop See you there!

Featured Article: PIM acting as a weak reversible inhibitor seems to compete for the same binding site as PAM on the P2Y12 receptor Marco Valgimigli Antonio Landi ahajrnls.org/4cROQav

ALT-SHOCK-2 trial in perspective - excellent editorial by David Morrow and Uwe Zeymer in April issue of #EHJACVC doi.org/10.1093/ehjacc… European Society of Cardiology Journals #DidYouKnow graphic made by Anna Oleksiak, MD PhD

Pretreat or not to pretreat: that is the question. Marco Valgimigli sciencedirect.com/science/articl…

Featured Article: PIM acting as a weak reversible inhibitor seems to compete for the same binding site as PAM on the P2Y12 receptor Marco Valgimigli Antonio Landi ahajrnls.org/4cROQav

European Society of Cardiology Manzo-Silberman Stephane Marta Kaluzna-Oleksy Radoslaw Parma Mario Iannaccone Dr Aleksandra Gąsecka Erik Rafflenbeul A.Nazmi Calik Alessandro Sticchi Maciej Lesiak Fabien Praz Nicole Karam, MD, PhD, FESC Francesco Saia Michal Hawranek Belén Cid Alvarez Eric Van Belle Joana Delgado Silva Carla Agatiello Stefan Harb 5. #EAPCI Summit .. Day 2️⃣ Napoli 🇮🇹 🌸#networking & #citysightseeing 🌸#move & #stretch break EAPCPresident 🌸🙏to #EAPCI board & NS & WG repr & European Society of Cardiology CEO, CSO & Violeta & Sara for their support See you all at #EuroPCR 🇫🇷#EAPCIfamily

ECG-based Detection of the Infarct-Related Artery in STEMI Patients Presenting (Predominantly) Without ST-Elevation! If you're at #EuroPCR in Paris this week, let's connect.

🫀#enVast on Stage at #EuroPCR2025 🩺 Prof Marco Valgimigli ➡️ Session: Novelty in No-Flow Management in STEMI Patients. Shared 6 European centers experience. 🩺 Dr Ahmed Abdelwahab ➡️ case using enVast to retrieve a valve fragment Newcastle Hospitals Claudio Montalto Dario Bongiovanni Matthias Bossard 🇺🇦

1-month #DAPT duration was associated w/ similar total NACE & MACCE & reduced total 🩸 risk compared w/ prolonged DAPT. Findings support the use of an abbreviated duration of DAPT after #PCI in high 🩸 risk patients. jacc.org/doi/10.1016/j.… #EuroPCR #JACC Marco Valgimigli Dario Bongiovanni

I was privileged to celebrate today @PCR the memory of Tiziana Zaro and dedicate her one sub-analysis of @masterdapt which we thought it was special and unique as she has been and will continue to be for us

Congratulations to the 5 exceptional young Interventional Cardiologists who received their #EAPCI Grants in the Main Arena at #EuroPCR 2025 The future of our profession is bright

Giving a P2Y12 inhibitor to patients with coronary artery disease is associated with lower rates of myocardial infarction and stroke compared with traditional aspirin, with no increased risk of major bleeding, finds this study Marco Valgimigli bmj.com/content/389/bm…

I am pleased to announce that the new Impact Factor of EuroIntervention is the highest in its 20-year history: 9.5. Ranked 16th out of 230 journals in the cardiovascular category (+5 positions versus the previous year). Thank you all — it’s an exciting rollercoaster.